MOOD CONTROL CONDITION

N.K. Awasthi

doi:10.5281/zenodo.22052405

Abstract

Major depression, also known simply as depression, is a Common mood disturbed defined by symptoms of low
mood and an inability to feel pleasure (also known as anhedonia). The appearance of this condition has been
recognized and treated for millennia, with possible receiving a great deal of attention over the past several
decades. But what about prevention of depression? Can steps be taken ahead of time to protect against its
development? This is what depressions may sound like. Many of us feel sad, overwhelmed or depressed when life
becomes challenging, we lose someone we love or our self-esteem is injured. But when these feelings last for long
periods of time and affect our daily living, then it is important to reach out and get help.

Keywords

Depression, Anhedonia, Pleasure, Injured

References

1) World Health Organization. (2018). Depression: Key facts. https://www.who.int/news-room/factsheets/detail/depression
2) Pilling, S., Anderson, I., Goldberg, D., Meader, N., Taylor, C., & Two Guideline Development Groups.
(2009). Depression in adults, including those with a chronic physical health problem: Summary of
NICE guidance. BMJ, 339, b4108. https://doi.org/10.1136/bmj.b4108
3) Lewinsohn, P. M., Solomon, A., Seeley, J. R., & Zeiss, A. (2000). Clinical implications of
“subthreshold” depressive symptoms. Journal of Abnormal Psychology, 109, 345–351.
https://doi.org/10.1037/0021-843X.109.2.345
4) McCrea, R. L., Sammon, C. J., Nazareth, I., & Petersen, I. (2016). Initiation and duration of selective
serotonin reuptake inhibitor prescribing over time: UK cohort study. British Journal of Psychiatry,
209, 421–426. https://doi.org/10.1192/bjp.bp.115.166975
5) Moore, M., Yuen, H. M., Dunn, N., Mullee, M. A., Maskell, J., & Kendrick, T. (2009). Explaining the
rise in antidepressant prescribing: A descriptive study using the General Practice Research Database.
BMJ, 339, b3999. https://doi.org/10.1136/bmj.b3999
6) Wiles, N., Thomas, L., Abel, A., Ridgway, N., Turner, N., Campbell, J., et al. (2013). Cognitive
behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment
resistant depression: Results of the CoBalT randomised controlled trial. The Lancet, 381, 375–384.
https://doi.org/10.1016/S0140-6736(12)61552-9
7) Viola, S., & Moncrieff, J. (2016). Claims for sickness and disability benefits owing to mental disorders
in the UK: Trends from 1995 to 2014. BJPsych Open, 2, 18–24.
https://doi.org/10.1192/bjpo.bp.115.002246
8) McManus, S., Bebbington, P., Jenkins, R., & Brugha, T. (2016). Mental health and wellbeing in
England : Adult Psychiatric Morbidity Survey 2014. NHS Digital.
9) Hewlett, E., & Moran, V. (2014). Making mental health count: The social and economic costs of
neglecting mental health care. OECD Publishing. https://doi.org/10.1787/9789264208445-en
10) Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., et al. (2018).
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults
with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391,
1357–1366. https://doi.org/10.1016/S0140-6736(17)32802-7
11) Leurent, B., Gomes, M., Faria, R., Morris, S., Grieve, R., & Carpenter, J. R. (2018). Sensitivity analysis
for not-at-random missing data in trial-based cost-effectiveness analysis: A tutorial.
PharmacoEconomics, 36, 889–901. https://doi.org/10.1007/s40273-018-0650-5
12) Duffy, L., Bacon, F., Clarke, C. S., Donkor, Y., Freemantle, N., Gilbody, S., et al. (2019). A randomised
controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing
relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER):
Study protocol for a randomised controlled trial. Trials, 20, 1–13. https://doi.org/10.1186/s13063-019-
3390-8
13) Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35, 1095–1108.
https://doi.org/10.1097/00005650-199711000-00002
14) Franklin, M., Enrique, A., Palacios, J., & Richards, D. (2021). Psychometric assessment of EQ-5D-5L
and ReQoL measures in patients with anxiety and depression: Construct validity and responsiveness.
Quality of Life Research, 30, 2633–2647. https://doi.org/10.1007/s11136-021-02833-1
15) Clarke, C. S., Duffy, L., Lewis, G., Freemantle, N., Gilbody, S., Kendrick, T., et al. (2021). Cost-utility
analysis of discontinuing antidepressants in England primary care patients compared with long-term
maintenance: The ANTLER study. Applied Health Economics and Health Policy.
https://doi.org/10.1007/s40258-021-00693-x
16) Lewis, G., Duffy, L., Ades, A., Amos, R., Araya, R., Brabyn, S., et al. (2019). The clinical effectiveness
of sertraline in primary care and the role of depression severity and duration (PANDA): A pragmatic,
double-blind, placebo-controlled randomised trial. The Lancet Psychiatry, 6, 903–914.
https://doi.org/10.1016/S2215-0366(19)30366-9
17) Button, K. S., Kounali, D., Thomas, L., Wiles, N. J., Peters, T. J., Welton, N. J., et al. (2015). Minimal
clinically important difference on the Beck Depression Inventory–II according to the patient’s
perspective. Psychological Medicine, 45, 3269–3279. https://doi.org/10.1017/S0033291715001270
18) National Institute for Health and Care Excellence. (2013). Guide to the methods of technology
appraisal 2013. NICE.
19) Hotopf, M. (2002). The pragmatic randomised controlled trial. Advances in Psychiatric Treatment, 8,
326–333. https://doi.org/10.1192/apt.8.5.326
20) Gusmão, R., Quintão, S., McDaid, D., A rensman, E., Van Audenhove, C., Coffey, C., et al. (2013).
Antidepressant utilization and suicide in Europe: An ecological multi-national study. PLOS ONE, 8,
e66455. https://doi.org/10.1371/journal.pone.0066455